Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in T-Therapeutics’ £48 Million Series A funding round alongside leading European and US life science investors Sofinnova Partners, F-Prime Capital and Digitalis Ventures, with participation from Sanofi Ventures and the University of Cambridge Venture Fund.

T-Therapeutics spun out of the University of Cambridge and is based on the pioneering research into T-cell receptor (TCR) therapies that its founder, Professor Allan Bradley, carried out at both the University and the Wellcome Sanger Institute. The company was created to harness the power of T cell biology to create safe and effective treatments for many cancers and autoimmune diseases. The investment will be used to further the discovery and development of novel T cell receptor (TCR) therapeutics for cancer treatment, as well as autoimmune and inflammatory disorders.

The team at T-Therapeutics includes highly experienced antibody engineers and drug developers, many of whom were responsible for the creation of the Kymab and PetMedix antibody discovery platforms and pipelines. CIC invested in PetMedix until it was acquired by Zoetis in September this year. Subsequent to the financing, CIC’s partner, Robert Tansley joined T-Therapeutics Board.

Professor Allan Bradley, CEO of T-Therapeutics, commented:

“We’re delighted to have raised this Series A with such high-quality investors whose amazing networks and shared vision will help us deliver highly differentiated TCR cancer therapies. TCR therapeutics are very much at the dawn of their potential. We intend to replicate the success of therapeutic antibodies but build on this in a new dimension, by using the targeting domains of TCR receptors to take advantage of their much greater specificity for cancer cells compared to normal cells. Our OpTiMus platform provides an unbeatable starting point, a vast repertoire of unique, fully human TCRs, with the properties to make them ideal to develop into drugs.”

Dr. Robert Tansley, Partner at Cambridge Innovation Capital and board member of T-Therapeutics, said:

“T-Therapeutics is a great example of the world-class research and entrepreneurship taking place in Cambridge, built on the pioneering work Professor Allan Bradley and his team carried out at the Wellcome Sanger Institute and the University of Cambridge. We are delighted to be working with Allan and his team again. T-Therapeutics is representative of the high quality translational science coming out of the University of Cambridge and the Wellcome Sanger Institute which can have significant impact on important areas of unmet medical need”.